Lyme disease: diagnosis and treatment.
Journal
Current opinion in rheumatology
ISSN: 1531-6963
Titre abrégé: Curr Opin Rheumatol
Pays: United States
ID NLM: 9000851
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
pubmed:
7
3
2020
medline:
26
1
2021
entrez:
7
3
2020
Statut:
ppublish
Résumé
Lyme disease is an important, vector-borne infection found throughout the temperate Northern hemisphere. The disease causes rash, acute systemic illness, and in some untreated patients, inflammatory arthritis. This review examines the emergence, clinical features and management of early Lyme disease and Lyme arthritis. There has been continuing progress in characterizing the clinical manifestations, diagnostic testing and treatment of Lyme disease. Almost all patients with early Lyme disease can be cured with antibiotic treatment. In most cases, Lyme arthritis also responds to antibiotics, but some patients require additional treatment approaches. The diagnosis of Lyme disease is based on clinical manifestations and adjunctive laboratory testing. For the rheumatologist, Lyme arthritis should be recognized by a pattern of attacks of asymmetric, oligo-arthritis, recognizable by clinical manifestations in the same way that other rheumatic diseases, such as gout or rheumatoid arthritis, are diagnosed.
Identifiants
pubmed: 32141956
doi: 10.1097/BOR.0000000000000698
pii: 00002281-202005000-00007
doi:
Substances chimiques
Anti-Bacterial Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
247-254Références
Steere AC, Malawista SE, Snydman DR, et al. Lyme arthritis: an epidemic of oligoarticular arthritis in children and adults in three Connecticut communities. Arthritis Rheum 1977; 20:7–17.
Mead PS. Epidemiology of Lyme disease. Infect Dis Clin North Am 2015; 29:187–210.
Steere AC, Strle F, Wormser GP, et al. Lyme borreliosis. Nat Rev Dis Primers 2016; 2:16090.
Bacon RM, Kugeler KJ, Mead PS. Surveillance for Lyme disease--United States, 1992–2006. MMWR Surveill Summ 2008; 57:1–9.
Burgdorfer W, Barbour AG, Hayes SF, et al. Lyme disease-a tick-borne spirochetosis? Science 1982; 216:1317–1319.
Stanek G, Wormser GP, Gray J, Strle F. Lyme borreliosis. Lancet 2012; 379:461–473.
Maraspin V, Mrvic T, Ruzic-Sabljic E, et al. Acrodermatitis chronica atrophicans in children: report on two cases and review of the literature. Ticks Tick Borne Dis 2019; 10:180–185.
Steere AC. Lyme disease. N Engl J Med 1989; 321:586–596.
Steere AC, Angelis SM. Therapy for Lyme arthritis: strategies for the treatment of antibiotic-refractory arthritis. Arthritis Rheum 2006; 54:3079–3086.
Arvikar SL, Steere AC. Diagnosis and treatment of Lyme arthritis. Infect Dis Clin North Am 2015; 29:269–280.
Reid MC, Schoen RT, Evans J, et al. The consequences of overdiagnosis and overtreatment of Lyme disease: an observational study. Ann Intern Med 1998; 128:354–362.
White J, Noonan-Toly C, Lukacik G, et al. Lyme disease surveillance in New York State: an assessment of case underreporting. Zoonoses Public Health 2018; 65:238–246.
Schiffman EK, McLaughlin C, Ray JAE, et al. Underreporting of Lyme and other tick-borne diseases in residents of a high-incidence county, Minnesota, 2009. Zoonoses Public Health 2018; 65:230–237.
Nelson CA, Saha S, Kugeler KJ, et al. Incidence of clinician-diagnosed Lyme disease, United States, 2005–2010. Emerg Infect Dis 2015; 21:1625–1631.
Poinar G. Spirochete-like cells in a Dominican amber Ambylomma tick (Arachnida: Ixodidae). Historical Biol 2015; 27:565–570.
Spielman A. The emergence of Lyme disease and human babesiosis in a changing environment. Ann N Y Acad Sci 1994; 740:146–156.
Schwartz AM, Hinckley AF, Mead PS, et al. Surveillance for Lyme Disease - United States, 2008–2015. MMWR Surveill Summ 2017; 66:1–12.
Clow KM, Leighton PA, Ogden NH, et al. Northward range expansion of Ixodes scapularis evident over a short timescale in Ontario, Canada. PLoS One 2017; 12:e0189393.
Bowman D, Little SE, Lorentzen L, et al. Prevalence and geographic distribution of Dirofilaria immitis, Borrelia burgdorferi, Ehrlichia canis, and Anaplasma phagocytophilum in dogs in the United States: results of a national clinic-based serologic survey. Vet Parasitol 2009; 160:138–148.
Kugeler KJ, Farley GM, Forrester JD, Mead PS. Geographic distribution and expansion of human Lyme disease, United States. Emerg Infect Dis 2015; 21:1455–1457.
Nadelman RB. Erythema migrans. Infect Dis Clin North Am 2015; 29:211–239.
Nigrovic LE, Neville DN, Balamuth F, et al. A minority of children diagnosed with Lyme disease recall a preceding tick bite. Ticks Tick Borne Dis 2019; 10:694–696.
Smith RP, Schoen RT, Rahn DW, et al. Clinical characteristics and treatment outcome of early Lyme disease in patients with microbiologically confirmed erythema migrans. Ann Intern Med 2002; 136:421–428.
Wormser GP, McKenna D, Carlin J, et al. Brief communication: hematogenous dissemination in early Lyme disease. Ann Intern Med 2005; 142:751–755.
Robinson ML, Kobayashi T, Higgins Y, et al. Lyme carditis. Infect Dis Clin North Am 2015; 29:255–268.
N’Guyen Y, Lesaffre F, Metz D, et al. No serological evidence for Borrelia burgdorferi sensu lato infection in patients with dilated cardiomyopathy in Northern France. Infect Dis (Lond) 2016; 48:763–764.
Guet-Revillet H, Levy C, Vallet C, et al. Lyme neuroborreliosis in children: Report of nine cases and a review of the literature. Arch Pediatr 2019; 26:133–137.
Koedel U, Pfister HW. Lyme neuroborreliosis. Curr Opin Infect Dis 2017; 30:101–107.
Pachner AR. CNS Lyme disease. Neurology 1992; 42:1849–1850.
Halperin JJ. Lyme neuroborreliosis. Current opinion in infectious diseases 2019; 32:259–264.
Visser AE, Verduyn Lunel FM, Veldink JH, van den Berg LH. No association between Borrelia burgdorferi antibodies and amyotrophic lateral sclerosis in a case-control study. Eur J Neurol 2017; 24:227–230.
Steere AC, Schoen RT, Taylor E. The clinical evolution of Lyme arthritis. Ann Intern Med 1987; 107:725–731.
Grillon A, Scherlinger M, Boyer PH, et al. Characteristics and clinical outcomes after treatment of a national cohort of PCR-positive Lyme arthritis. Semin Arthritis Rheum 2019; 48:1105–1112.
Schoen RT. A case revealing the natural history of untreated Lyme disease. Nat Rev Rheumatol 2011; 7:179–184.
Horton DB, Taxter AJ, Davidow AL, et al. Pediatric antibiotic-refractory Lyme arthritis: a multicenter case-control study. J Rheumatol 2019; 46:943–951.
Branda JA, Body BA, Boyle J, et al. Advances in serodiagnostic testing for Lyme disease are at hand. Clin Infect Dis 2018; 66:1133–1139.
Schutzer SE, Body BA, Boyle J, et al. Direct diagnostic tests for Lyme disease. Clin Infect Dis 2019; 68:1052–1057.
Ruzic-Sabljic E, Cerar T. Progress in the molecular diagnosis of Lyme disease. Expert Rev Mol Diagn 2017; 17:19–30.
Theel ES. The past, present, and (possible) future of serologic testing for Lyme disease. J Clin Microbiol 2016; 54:1191–1196.
Marques AR. Laboratory diagnosis of Lyme disease: advances and challenges. Infect Dis Clin North Am 2015; 29:295–307.
Alasel M, Keusgen M. Promising alternatives for one-tier testing of Lyme borreliosis. Clin Chim Acta 2018; 479:148–154.
Schoen RT. Editorial commentary: better laboratory testing for Lyme disease: no more western blot. Clin Infect Dis 2013; 57:341–343.
Webber BJ, Burganowski RP, Colton L, et al. Lyme disease overdiagnosis in a large healthcare system: a population-based, retrospective study. Clin Microbiol Infect 2019; 25:1233–1238.
Markowicz M, Kivaranovic D, Stanek G. Testing patients with nonspecific symptoms for antibodies against Borrelia burgdorferi sensu lato does not provide useful clinical information about their aetiology. Clin Microbiol Infect 2015; 21:1098–1103.
Lantos PM, Branda JA, Boggan JC, et al. Poor positive predictive value of Lyme disease serologic testing in an area of low disease incidence. Clin Infect Dis 2015; 61:1374–1380.
Richardson M, Khouja C, Sutcliffe K. Interventions to prevent Lyme disease in humans: A systematic review. Prev Med Rep 2019; 13:16–22.
Gomes-Solecki M, Arnaboldi PM, Backenson PB, et al. Protective immunity and new vaccines for Lyme disease. Clin Infect Dis 2019; pii: ciz872.
pii: ciz872
Nadelman RB, Nowakowski J, Fish D, et al. Prophylaxis with single-dose doxycycline for the prevention of Lyme disease after an Ixodes scapularis tick bite. N Engl J Med 2001; 345:79–84.
Strle F, Stupica D, Bogovic P, et al. Is the risk of early neurologic Lyme borreliosis reduced by preferentially treating patients with erythema migrans with doxycycline? Diagn Microbiol Infect Dis 2018; 91:156–160.
Treatment of Lyme disease. JAMA 2016; 315:2461–2462.
Waddell LA, Greig J, Lindsay LR, et al. A systematic review on the impact of gestational Lyme disease in humans on the fetus and newborn. PLoS One 2018; 13:e0207067.
Maraspin V, Bogovic P, Rojko T, et al. Early lyme borreliosis in patients treated with tumour necrosis factor-alfa inhibitors. J Clin Med 2019; 8: pii: E1857.
pii: e1857
Maraspin V, Bogovic P, Rojko T, et al. Erythema migrans: course and outcome in patients treated with rituximab. Open Forum Infect Dis 2019; 6:ofz292.
Wormser GP, Dattwyler RJ, Shapiro ED, et al. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2006; 43:1089–1134.
Sanchez E, Vannier E, Wormser GP, Hu LT. Diagnosis, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: a review. JAMA 2016; 315:1767–1777.
Terekhova D, Sartakova ML, Wormser GP, et al. Erythromycin resistance in Borrelia burgdorferi. Antimicrob Agents Chemother 2002; 46:3637–3640.
Luft BJ, Dattwyler RJ, Johnson RC, et al. Azithromycin compared with amoxicillin in the treatment of erythema migrans. A double-blind, randomized, controlled trial. Ann Intern Med 1996; 124:785–791.
Cadavid D, Auwaerter PG, Rumbaugh J, Gelderblom H. Antibiotics for the neurological complications of Lyme disease. Cochrane Database Syst Rev 2016; 12:CD006978.
Dersch R, Freitag MH, Schmidt S, et al. Efficacy and safety of pharmacological treatments for acute Lyme neuroborreliosis - a systematic review. Eur J Neurol 2015; 22:1249–1259.
Ljostad U, Skogvoll E, Eikeland R, et al. Oral doxycycline versus intravenous ceftriaxone for European Lyme neuroborreliosis: a multicentre, noninferiority, double-blind, randomised trial. Lancet Neurol 2008; 7:690–695.
Centers for Disease Control and Prevention (CDC).. Three sudden cardiac deaths associated with Lyme carditis - United States, November 2012-July 2013. MMWR Morb Mortal Wkly Rep 2013; 62:993–996.
Schoen R. Musculoskeletal manifestations of Lyme disease. Waltham, MA. 2009-Present.
Dattwyler RJ, Halperin JJ, Volkman DJ, Luft BJ. Treatment of late Lyme borreliosis--randomised comparison of ceftriaxone and penicillin. Lancet 1988; 1:1191–1194.
Bentas W, Karch H, Huppertz HI. Lyme arthritis in children and adolescents: outcome 12 months after initiation of antibiotic therapy. J Rheumatol 2000; 27:2025–2030.
Wormser GP, McKenna D, Scavarda C, Karmen C. Outcome of facial palsy from Lyme disease in prospectively followed patients who had received corticosteroids. Diagn Microbiol Infect Dis 2018; 91:336–338.
Jowett N, Gaudin RA, Banks CA, Hadlock TA. Steroid use in Lyme disease-associated facial palsy is associated with worse long-term outcomes. Laryngoscope 2017; 127:1451–1458.
Nimmrich S, Becker I, Horneff G. Intraarticular corticosteroids in refractory childhood Lyme arthritis. Rheumatol Int 2014; 34:987–994.
Horton DB, Taxter AJ, Davidow AL, et al. Intraarticular glucocorticoid injection as second-line treatment for Lyme arthritis in children. J Rheumatol 2019; 46:952–959.
Lochhead RB, Strle K, Kim ND, et al. MicroRNA expression shows inflammatory dysregulation and tumor-like proliferative responses in joints of patients with postinfectious Lyme arthritis. Arthritis Rheumatol 2017; 69:1100–1110.
Schoen RT, Aversa JM, Rahn DW, Steere AC. Treatment of refractory chronic Lyme arthritis with arthroscopic synovectomy. Arthritis Rheum 1991; 34:1056–1060.
Wormser GP, Weitzner E, McKenna D, et al. Long-term assessment of health-related quality of life in patients with culture-confirmed early Lyme disease. Clin Infect Dis 2015; 61:244–247.
Wormser GP, Weitzner E, McKenna D, et al. Long-term assessment of fatigue in patients with culture-confirmed Lyme disease. The American journal of medicine 2015; 128:181–184.
Wormser GP, Weitzner E, McKenna D, et al. Long-term assessment of fibromyalgia in patients with culture-confirmed Lyme disease. Arthritis Rheumatol 2015; 67:837–839.
Aucott JN. Posttreatment Lyme disease syndrome. Infect Dis Clin North Am 2015; 29:309–323.
Rebman AW, Bechtold KT, Yang T, et al. The clinical, symptom, and quality-of-life characterization of a well defined group of patients with posttreatment Lyme disease syndrome. Front Med 2017; 4:224.
DeLong A, Hsu M, Kotsoris H. Estimation of cumulative number of posttreatment Lyme disease cases in the US, 2016 and 2020. BMC Public Health 2019; 19:352.
Lantos PM. Chronic Lyme disease. Infect Dis Clin North Am 2015; 29:325–340.
Berende A, ter Hofstede HJ, Vos FJ, et al. Randomized trial of longer-term therapy for symptoms attributed to Lyme disease. N Engl J Med 2016; 374:1209–1220.
Berende A, Ter Hofstede HJM, Vos FJ, et al. Effect of prolonged antibiotic treatment on cognition in patients with Lyme borreliosis. Neurology 2019; 92:e1447–e1455.
Marzec NS, Nelson C, Waldron PR, et al. Serious bacterial infections acquired during treatment of patients given a diagnosis of chronic Lyme disease - United States. MMWR Morb Mortal Wkly Rep 2017; 66:607–609.
De Wilde M, Speeckaert M, Callens R, Van Biesen W. Ceftriaxone-induced immune hemolytic anemia as a life-threatening complication of antibiotic treatment of ’chronic Lyme disease’. Acta clinica Belgica 2017; 72:133–137.
Lantos PM, Shapiro ED, Auwaerter PG, et al. Unorthodox alternative therapies marketed to treat Lyme disease. Clin Infect Dis 2015; 60:1776–1782.